Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 30 June 2022.

Key highlights for the quarter included:

-- First ever trial studying NK cells in combination with IL-2 and Vactosertib is being undertaken with Chimeric’s CORE NK platform cells
-- Expanded license agreement with the University of Pennsylvania (Penn) related to CDH17 chimeric antigen receptor (CAR) therapies
-- Manufacturing and quality release for CHM 1101 (CLTX CAR T) viral vector, a key development milestone, is complete
-- Entered into strategic manufacturing partnership with Wuxi Advanced Therapies
-- Exercised exclusive option for the CORE-NK platform from Case Western Reserve University (CWRU) and proceeded with negotiations for an exclusive license
-- Entered into an Equity Placement Agreement for up to A$30 million with L1 Capital

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.